Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Bristol-Myers Squibb186 enrolled

Overview

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.

Study Type

OBSERVATIONAL

Enrollment

186

Conditions

Chronic Myeloid Leukemia (CML)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Age \>18 years * International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x) * At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013 * Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib) Exclusion Criteria: * History of bone marrow or stem cell transplant as identified in the 6 month pre-period

Locations (1)

Franklin Pharmaceutical Consulting, Llc

Clinton, South Carolina, United States

Outcomes

Primary Outcomes

Healthcare costs

Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy

Time frame: Intent-to-treat (ITT) at 6 months

Secondary Outcomes

Healthcare costs by line of therapy

Time frame: Intent-to-treat (ITT) at 6 months

Resource utilization by line of therapy

Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions

Time frame: Intent-to-treat (ITT) at 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.